Kymera Therapeutics, Inc. (KYMR) Institutional Ownership

Ownership Summary

Recent 13F filings as of September 2025 show that 212 institutional investors hold a position in Kymera Therapeutics, Inc. (NASDAQ:KYMR).

• These investors collectively held 113.2% of the company's total shares outstanding in September 2025, down from 120.4% in June 2025.
• In percentage terms, this reflects as a holdings change of 5.17% quarter on quarter, and an increase of 21.14% year over year.
• During the quarter, 114 institutions bought more Kymera Therapeutics shares, 64 sold shares, and 34 of the 212 total investors held their position steady.
• This class of investors increased its holdings in Kymera Therapeutics to 80.90Mn shares for the 13F-cycle ending September 2025, up by 3.98Mn shares quarter on quarter, and up 12.10Mn shares year over year.
• With 6.65Mn shares, BAKER BROS. ADVISORS LP commands the largest institutional position in Kymera Therapeutics as of September 30, 2025, equating to 9.30% of the company.
• Among the most significant buyers of Kymera Therapeutics during September 2025 were Holocene Advisors, LP (840.33K), Alyeska Investment Group, L.P. (565.09K), FEDERATED HERMES, INC. (558.67K), T. Rowe Price Investment Management, Inc. (520.59K), STATE STREET CORP (465.02K).
• Leading sellers of Kymera Therapeutics stock in September 2025 included PRICE T ROWE ASSOCIATES INC /MD/ (1.76Mn), Woodline Partners LP (250.11K), Avoro Capital Advisors LLC (205.56K), VANGUARD GROUP INC (198.13K), WELLINGTON MANAGEMENT GROUP LLP (176.37K).
• The top 10 institutional holders of Kymera Therapeutics for the quarter ending September 2025 included BAKER BROS. ADVISORS LP (6.65Mn), Avoro Capital Advisors LLC (6.35Mn), FMR LLC (5.88Mn), BVF INC/IL (5.50Mn), VANGUARD GROUP INC (5.42Mn), WELLINGTON MANAGEMENT GROUP LLP (5.20Mn), PRICE T ROWE ASSOCIATES INC /MD/ (5.10Mn), Atlas Venture Life Science Advisors, LLC (4.90Mn), BlackRock, Inc. (4.37Mn), Siren, L.L.C. (3.43Mn).